CD93 and neoplasm: Sun and colleagues also reported that overexpression of the IGFBP7-CD93 pathway in patients who received anti-PD-1/PD-L1 treatment was related to worse treatment effect, and blocking this axis by CD93-neutralizing antibody could promote tumor therapy by regulating the TME [9].